Renaissance Technologies (RenTech)'s NTLA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.4 M shares of Intellia Therapeutics, Inc. (NTLA) worth $23.69 M, representing 0.03% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in NTLA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 1.4 M shares. Largest reduction occurred in Q1 2026, reducing 1.67 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +1.4 M | New Buy | 1.4 M | $16.92 |
| Q1 2026 | -1.67 M | Sold Out | 0 | $0.00 |
| Q4 2025 | +1.02 M | Add 156.94% | 1.67 M | $8.99 |
| Q3 2025 | -25,900 | Reduce 3.83% | 651,000 | $17.27 |
| Q2 2025 | +676,900 | New Buy | 676,900 | $9.38 |
| Q1 2025 | -98,700 | Sold Out | 0 | $0.00 |
| Q4 2024 | +98,700 | New Buy | 98,700 | $11.66 |
| Q3 2024 | -38,700 | Sold Out | 0 | $0.00 |
| Q2 2024 | +38,700 | New Buy | 38,700 | $22.38 |
| Q1 2024 | -13,397 | Sold Out | 0 | $0.00 |
| Q4 2023 | +13,397 | New Buy | 13,397 | $30.45 |
| Q2 2023 | -16,554 | Sold Out | 0 | $0.00 |
| Q1 2023 | +16,554 | New Buy | 16,554 | $0.04 |
| Q3 2022 | -119,600 | Sold Out | 0 | $0.00 |
| Q2 2022 | +119,600 | New Buy | 119,600 | $51.76 |
| Q3 2020 | -41,000 | Sold Out | 0 | $0.00 |
| Q2 2020 | +41,000 | New Buy | 41,000 | $21.02 |
| Q1 2020 | -36,700 | Sold Out | 0 | $0.00 |
| Q4 2019 | +36,700 | New Buy | 36,700 | $14.66 |
| Q3 2019 | -164,600 | Sold Out | 0 | $0.00 |
| Q2 2019 | +164,600 | New Buy | 164,600 | $16.37 |
| Q1 2019 | -228,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +228,000 | New Buy | 228,000 | $13.65 |
| Q3 2017 | -19,200 | Sold Out | 0 | $0.00 |
| Q2 2017 | +19,200 | New Buy | 19,200 | $15.99 |
Renaissance Technologies (RenTech)'s Intellia Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Intellia Therapeutics, Inc. (NTLA) in Q2 2017, acquiring 19,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Intellia Therapeutics, Inc. (NTLA) for 25 quarters since Q2 2017.
Renaissance Technologies (RenTech)'s largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q2 2026, adding 1,400,004 shares worth $23.69 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,400,004 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $23.69 M.
As of the Q2 2026 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 0.03% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Intellia Therapeutics, Inc. (NTLA) was 1,672,700 shares, as reported at the end of Q4 2025.